Status:
COMPLETED
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Urothelial Carcinoma
Carcinoma, Non-Small Cell Lung
Eligibility:
All Genders
Brief Summary
This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical...
Eligibility Criteria
Inclusion
- Participants who are administered with atezolizumab for the locally approved indications
Exclusion
- Participants with a known hypersensitivity to atezolizumab or to any of the excipients
Key Trial Info
Start Date :
November 29 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 12 2022
Estimated Enrollment :
1758 Patients enrolled
Trial Details
Trial ID
NCT03232593
Start Date
November 29 2017
End Date
August 12 2022
Last Update
August 24 2022
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongnam Inst.of Radiological & Medical Sciences
Busan, South Korea, 46033
2
Inje University Busan Paik Hospital
Busan, South Korea, 47392
3
Inje university Haeundae Paik Hospital
Busan, South Korea, 48108
4
Dong-A University Hospital
Busan, South Korea, 49201